DRUG TREATMENT OF PATIENTS WITH THE HISTORY OF ACUTE STROKE: DATA OF THE PILOT PHASE OF THE OUTPATIENT REGISTRY «REGION»

Aim. To study the pharmacological treatment of patients with acute stroke (AS) within the prospective outpatient registries.

Material and methods. In the pilot phase of the study, conducting on the base of one of the out-patient clinic in Ryazan city, 200 and 115 patients were included into the outpatient registry of patients with AS history of any remoteness (AS-AR registry), and outpatient registry of the first apply (AS-FA registry) to the out-patient clinic after stroke, respectively. The correspondence of the prescribed and actually taken drug therapy to clinical recommendations, its continuity, and the adherence of patients to treatment were assessed during the prospective observation.

Results. Most patients did not receive adequate therapy to reduce the risk of AS and other cardiovascular complications in the outpatient stage, especially in the period prior to the reference AS. Drugs with a proven beneficial effect on the prognosis in the post-stroke period were prescribed significantly (p and after 2 years – in the AS-FA registry, the frequency of the therapy was not significantly different from the frequency of prescribing at the stage of inclusion in the registers, with the exception of statins (they were taken 1.7 and 1.5 times less frequently). Prognostically significant prescriptions of the inclusion phase were performed in the long-term follow-up period in 49% and 70% of patients (on average 58%), respectively; however, the frequency of first-time therapy was 44% and 19% of the total number of prescriptions in this period, respectively. Adherence to treatment, according to the Morisky-Green questionnaire, was revealed in 17.7 and 51.7% of patients, respectively

Conclusion. The results of the pilot phase of the REGION study (AS-AR and AS-FA outpatient registries) showed that the quality of the prescribed drug therapy of patients in out-patient clinic is inadequate. A comparison of the data of AS-AR and AS-FA registries allows to make a preliminary conclusion that over the 5-year period separating the remoteness of AS development in these registries, the quality of patient treatment has significantly improved, although not enough. The proportion of previously performed prognostically significant prescriptions averaged only about 60% at the stage of the further prospective follow-up. In general, during the observation period, taking into account newly made prescriptions, the frequency of adequate drug therapy during the observation period decreased only for statins. Most patients were not sufficiently committed to pharmacological treatment according to the Morisky-Green questionnaire.

1. Benjamin E.J., Blaha M.J., Chiuve S.E., et al. Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association. Circulation. 2017;135(10):e146-e603.

2. Demographic Yearbook of Russia, 2015. Statistical Yearbook. Moscow: Rosstat; 2015. (In Russ.) [Демографический ежегодник России 2015. Статистический сборник. Москва: Росстат; 2015].

3. Meschia J.F., Bushnell C., Boden-Albala B., et al. Guidelines for the Primary Prevention of Stroke. Stroke. 2014;45(12):3754-832.

4. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37:2315-81.

5. Kernan W.N., Ovbiagele B., Black H.R., et al. Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Stroke. 2014;45(7):2160-236.

6. Bangalore S., Schwamm L., Smith E.E., et al. Secondary prevention after ischemic stroke or transient ischemic attack. Get With the Guidelines-Stroke Steering Committee and Investigators. The American Journal of Medicine. 2014;127(8):728-38.

7. Smith Е.E., Saver J.L., Alexander D.N., et al. Clinical Performance Measures for Adults Hospitalized With Acute Ischemic Stroke: Performance Measures for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2014;45(11):3472-98.

8. Winstein C.J., Stein J., Arena R., et al. Guidelines for Adult Stroke Rehabilitation and Recovery. Stroke. 2016;47(6):e98-e169.

9. Lenti L., Bereczki D., Brainin M., et al. Stroke care in the central Eastern Europe: current problems and call for action. International Journal of Stroke. 2013;8(5):365-73.

10. Yusuf S., Islam S., Chow C.K., et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011;378(9798):1231-43.

11. Smith E.E., Saposnik G., Biesseet G.J., et al. Prevention of Stroke in Patients With Silent Cerebrovascular Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2017;48:e44-e71.

12. Shi G.M., Zhang Y.D., Geng C., et al. Nanjing First Hospital Stroke Registry Investigators. Profile and 1-Year Outcome of Ischemic Stroke in East China: Nanjing First Hospital Stroke Registry. Journal of Stroke and Cerebrovascular Diseases. 2016;25(1):49-56.

13. Amarenco P., LavallОe P.C., Labreuche J., et al. TIAregistry.org Investigators. One-Year Risk of Stroke after Transient Ischemic Attack or Minor Stroke. The New England Journal of Medicine. 2016;374(16):1533-42.

14. Ogawa H., Senoo K., An Y., et al. Clinical Features and Prognosis in Patients with Atrial Fibrillation and Prior Stroke: Comparing the Fushimi and Darlington AF Registries. EBioMedicine. 2017;18:199-203.

15. Boytsov S.А., Martsevich S.Yu., Ginzburg M.L., et al. Luberetskiy study of the mortality of patients who underwent cerebral stroke or transient ischemic attack (LIS-2). Design and evaluation of drug therapy.Rational Pharmacotherapy in Cardiology. 2013;9(2):114-22. (In Russ.) [Бойцов С.А., Марцевич С.Ю., Гинзбург М.Л., и др. Люберецкое исследование смертности больных, перенесших мозговой инсульт или транзиторную ишемическую атаку (ЛИС-2). Дизайн и оценка лекарственной терапии. Рациональная Фармакотерапия в Кардиологии. 2013;9(2):114-22].

16. Boytsov S.A., Lukyanov M.M., Yakushin S.S., et al. The registry of cardiovascular diseases (REQUAS): diagnosis, combined cardiovascular pathology, concomitant diseases and treatment in conditions of real outpatient and polyclinic practice. Kardiovaskulyarnaya Terapiya i Profilaktika. 2014;6:44-50. (In Russ.) [Бойцов С.А., Лукьянов М.М., Якушин С.С. и др. Регистр кардиоваскулярных заболеваний (РЕКВАЗА): диагностика, сочетанная сердечно-сосудистая патология, сопутствующие заболевания и лечение в условиях реальной амбулаторно-поликлинической практики. Кардиоваскулярная Терапия и Профилактика. 2014;6:44-50].

17. You J.J., Singer D.E., Howard P.A., et al. Antithrombotic Therapy for Atrial Fibrillation. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(Suppl):e531S-e575S.

18. Jiang Y., Yang X., Li Z., et al. Persistence of secondary prevention medication and related factors for acute ischemic stroke and transient ischemic attack in China. Neurological Research. 2017;19:1-6.

19. Andersson T., Magnuson A., Bryngelsson I.L., et al. Patients with atrial fibrillation and outcomes of cerebral infarction in those with treatment of warfarin versus no warfarin with references to CHA2DS2-VASc score, age and sex - A Swedish nationwide observational study with 48 433 patients. PLoS One. 2017;12(5):e0176846.

20. Macha K., Volbers B., Bobinger T., et al. Early Initiation of Anticoagulation with Direct Oral Anticoagulants in Patients after Transient Ischemic Attack or Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases. 2016;25(9):2317-21.

21. Xie W., Zheng F., Zhong B., et al. Long-Term Antiplatelet Mono- and Dual Therapies After Ischemic Stroke or Transient Ischemic Attack: Network Meta-Analysis. Journal of the American Heart Association. 2015; 4(8):e002259.

22. Niu P.P., Guo Z.N., Jin H., et al. Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis. BMJ Open. 2016;6(3):e009013.

23. Geary L., Aronius J., Wettermark B., et al. Sociodemographic factors are associated with utilization of statins after ischaemic stroke/TIA. International Journal of Clinical Practice. 2017;71(3-4).

24. Katsanos A.H., Filippatou A., Manios E., et al. Intensity of Blood Pressure Reduction and Secondary Stroke Prevention: A Systematic Review and Meta-regression Analysis of Randomized Clinical Trials. Hypertension. 2017;69:171-9.

25. Suvorov A.Yu., Martsevich S.Yu., Kutishenko N.P., et al. Evaluation of compliance with modern clinical recommendations of cardiovascular therapy aimed at improving outcomes in patients after a stroke (according to the LIS-2 registry). Rational Pharmacotherapy in Cardiology. 2015;11(3):247-52. (In Russ.) [Суворов А.Ю., Марцевич С.Ю., Кутишенко Н.П. и др. Оценка соответствия современным клиническим рекомендациям сердечно-сосудистой терапии, направленной на улучшение исходов у пациентов после перенесенного инсульта (по данным регистра ЛИС-2). Рациональная Фармакотерапия в Кардиологии. 2015;11(3):247-52].

26. Suvorov A.Yu., Martsevich S.Yu., Kutishenko N.P. Evaluation of the quality of therapy in the registries of acute cerebral circulation disorders. Foreign experience, the prospects of Russia. Kardiovaskulyarnaya Terapiya i Profilaktika. 2014; 13 (4): 81-6. (In Russ.) [Суворов А.Ю., Марцевич С.Ю., Кутишенко Н.П. Оценка качества терапии в регистрах острого нарушения мозгового кровообращения. Зарубежный опыт, перспективы России. Кардиоваскулярная Терапия и Профилактика. 2014;13(4):81-6].

27. Boytsov S.А., Martsevich S.Yu., Kutishenko N.P., et al. The Study "Register of Patients after Acute Stroke (REGION)". Part 1. Hospital Prospective Register of Patients after Acute Stroke (According to the Results of the Pilot Phase of the Study). Rational Pharmacotherapy in Cardiology. 2016; 12 (6): 645-53. (In Russ.) [Бойцов С.А., Марцевич С.Ю., Кутишенко Н.П., и др. Исследование "РЕГИстр больных, перенесших Острое Нарушение мозгового кровообращения (РЕГИОН)". Часть 1. Госпитальный проспективный регистр больных, перенесших острое нарушение мозгового кровообращения (по результатам пилотного этапа исследования). Рациональная Фармакотерапия в Кардиологии. 2016;12(6):645-53].

28. Boytsov S.A., Loukyanov M.M., Yakushin S.S., et al. The Study "Register of Patients after Acute Stroke (REGION)". Part 2. Outpatient Prospective Register of Patients after Acute Stroke (According to the Results of the Pilot Phase of the Study). Rational Pharmacotherapy in Cardiology. 2017;13(1):4-17. (In Russ.) [Бойцов С.А., Лукьянов М.М., Якушин С.С. и др. Исследование "РЕГИстр больных, перенесших Острое Нарушение мозгового кровообращения (РЕГИОН)". Часть 2. Амбулаторный проспективный регистр больных, перенесших острое нарушение мозгового кровообращения (по результатам пилотного этапа исследования). Рациональная Фармакотерапия в Кардиологии. 2017;13(1):4-17].

29. Morisky D.E., Green L.W., Levine D.M. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67-74.